Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants
Clinical trial NCT04495010 · WITHDRAWN
Trial details
- NCT number
- NCT04495010
- Sponsor
- Bristol-Myers Squibb
- Status
- WITHDRAWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-31
- Primary completion
- 2024-02-28
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.